Cargando…
Shared epitope and rheumatoid arthritis severity: association with infliximab treatment in a postmarketing study
Autores principales: | Marotte, H, Gaudin, P, Alexandre, C, Miossec, P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833617/ http://dx.doi.org/10.1186/ar680 |
Ejemplares similares
-
Circulating bioactive TNF in rheumatoid arthritis patients treated with infliximab: link to clinical response
por: Marotte, H, et al.
Publicado: (2003) -
Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients
por: Rinaudo-Gaujous, Mélanie, et al.
Publicado: (2019) -
The shared epitope revisited: shared epitope negative HLA-DR alleles influence susceptibility to rheumatoid arthritis
por: Reviron, D, et al.
Publicado: (2001) -
A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab
por: Marotte, Hubert, et al.
Publicado: (2007) -
Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response
por: Marotte, Hubert, et al.
Publicado: (2005)